Kennedy Returns to the Senate

Posted by Joe Arite on July 10th, 2008
Tags: Medicare, Senate, Senator Kennedy

Greeted by a standing ovation from senators on both sides of the aisle, Senator Ted Kennedy (D-MA) returned to the Senate floor on Wednesday for the first time since he was diagnosed with a malignant brain tumor in May.

His return brought a victory to a stalled Medicare bill. The Medicare Improvements for Patients Providers Act (HR 6331) was approved yesterday by a veto proof margin in the Senate. Now the 10.6 percent cut to physicians’ payments, which went into effect on July 1st, will be reversed.

Wearing a dark suit and a wide grin, Kennedy gave a grand gesture during the Medicare roll-call vote. “Aye,” he said, to laughter (The Hill, June 9, 2008).

“Everyone recognizes that was an act of courage,” Senate Majority Leader Harry Reid (D-NV) said. “I’ve been in the Senate for 27 years. I don’t quite remember another moment like it,” said Senator Chris Dodd (D-CT). “It was good to have the lion from Massachusetts back in the Senate.”

Kennedy’s presence Wednesday, along with the reality that Democrats had the votes lined up to move ahead, was enough to change the minds of 39 Republicans who previously voted against the bill. The bill was approved by a vote of 69-30, more than enough to override an anticipated presidential veto.

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions.

C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond where appropriate.

For the best response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Sign Our Petition

Guarantee access to colorectal cancer screening for all Americans who need it.

Get Involved

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe